There have been reports of acute pancreatitis in patients taking albiglutide during premarketing trials. Albiglutide has not been studied in patients with a history of pancreatitis to determine whether these patients are at increased risk for pancreatitis. Other antidiabetic therapies should be considered in patients with a history of pancreatitis. After initiation and dose increases, patients should be observed carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). Instruct patients to discontinue albiglutide promptly and to contact their physician if persistent, severe abdominal pain occurs; do not restart therapy if pancreatitis is confirmed. In March 2013, the FDA announced that it is evaluating unpublished findings that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients treated with incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. In February 2014, the FDA and EMA stated that after reviewing a number of clinical trials and animal studies, the current data does not support an increased risk of pancreatitis and pancreatic cancer in patients receiving incretin mimetics. The agencies have not reached any new conclusions about safety risks of the incretin mimetics, although they have expressed that the totality of the data that have been reviewed provides reassurance. Recommendations will be communicated once the review is complete; continue to consider precautions related to pancreatic risk until more data are available.
30 mg/kg/dose (Max: 1 gram/dose) IV or IM once daily for 1 to 3 days. High-dose pulse steroids may be considered as an alternative to a second infusion of IVIG or for retreatment of patients who have had recurrent or recrudescent fever after additional IVIG, but should not be used as routine primary therapy with IVIG in patients with Kawasaki disease. Corticosteroid treatment has been shown to shorten the duration of fever in patients with IVIG-refractory Kawasaki disease or patients at high risk for IVIG-refractory disease. A reduction in the frequency and severity of coronary artery lesions has also been reported with pulse dose methylprednisolone treatment.
In medical terms, it’s a benzodiazepine. It’s legally used for stress, anxiety and panic. Around school, however, it’s referred to as “bars,” “zanies” or “planks” and used to get a feeling similar to intoxication. This over-prescribed drug is becoming a staple in parents’ medicine cabinets, making it much easier for teens to access. What sets Xanax apart from all the other miscellaneous drugs in the medicine cabinet, though, is its ability to make the user black out, the high chance of addiction and the fact that withdrawal from Xanax is potentially deadly.